TheraRadar
← Back
Data updated: Jun 12, 2026

ASCENDIS

Pharma
MetabolicOncology Execution: Fair

ASCENDIS is a pharmaceutical company focused on Metabolic, Oncology. Key products include YUVIWEL.

2026
Since
1
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

ASCENDIS at a Glance

  • Fast trial execution (22 months median completion)

ASCENDIS's Key Drugs

ASCENDIS's core commercial portfolio centers on YUVIWEL, spanning Metabolic and Oncology — its most strategically important drugs approved in the last 15 years.

YUVIWEL
Approved 2026

ASCENDIS's Recent FDA Approvals

ASCENDIS secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

YUVIWEL NDA
2026-02-27
navepegritide
1 INDICATIONS AND USAGE YUVIWEL ® is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). YUVIWEL is a C-type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. ( 1 ) This indication is approved under accelerated approval based on an improvement in annualized growth velocity . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1 )

ASCENDIS's Therapeutic Areas

ASCENDIS's approved drugs and pipeline span 2 therapeutic areas, led by Metabolic and Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Metabolic 71%
0 drugs Phase 3: 2 Phase 2: 1
Oncology 29%
0 drugs Phase 2: 1 Phase 1: 2

ASCENDIS's Top Competitors

ASCENDIS's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Merck big-pharma
Oncology, Metabolic
Baxter specialty
Oncology, Metabolic
Johnson & Johnson big-pharma
Oncology, Metabolic
GSK big-pharma
Oncology, Metabolic
Sanofi big-pharma
Metabolic, Oncology

ASCENDIS Pipeline Snapshot

ASCENDIS has 6 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 2 Phase 2 and 2 Phase 1.

2
Phase 3
2
Phase 2
2
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • YUVIWEL leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Metabolic pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 1/2 completed
  • • Speed: 22 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges